Mazen Noureddin1, Arun J Sanyal2. 1. Director, Fatty Liver Program and Associate Professor of Clinical Medicine, Division of Digestive and Liver Diseases, Comprehensive Transplant Program, Cedars-Sinai Medical Center, Los Angeles, California, USA. 2. Professor of Medicine, Physiology and Molecular Pathology, Division of Gastroenterology, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Abstract
PURPOSE OF REVIEW: Advancing our understanding of the mechanisms that underlie NASH pathogenesis. RECENT FINDINGS: Recent findings on NASH pathogenesis have expanded our understanding of its complexity including: (1) there are multiple parallel hits that lead to NASH; (2) the microbiota play an important role in pathogenesis, with bacterial species recently shown to accurately differentiate between NAFL and NASH patients; (3) the main drivers of liver cell injury are lipotoxicity caused by free fatty acids (FFAs) and their derivatives combined with mitochondrial dysfunction; (4) decreased endoplasmic reticulum (ER) efficiency with increased demand for protein synthesis/folding/repair results in ER stress, protracted unfolded protein response, and apoptosis; (5) upregulated proteins involved in multiple pathways including JNK, CHOP, PERK, BH3-only proteins, and caspases result in mitochondrial dysfunction and apoptosis; and (6) subtypes of NASH in which these pathophysiological pathways vary may require patient subtype identification to choose effective therapy. SUMMARY: Recent pathogenesis studies may lead to important therapeutic advances, already seen in patients treated with ACC, ASK1 and SCD1 inhibitors and FXR agonists. Further advancing our understanding of mechanisms underlying NASH pathogenesis and the complex interplay between them will be crucial for developing effective therapies.
PURPOSE OF REVIEW: Advancing our understanding of the mechanisms that underlie NASH pathogenesis. RECENT FINDINGS: Recent findings on NASH pathogenesis have expanded our understanding of its complexity including: (1) there are multiple parallel hits that lead to NASH; (2) the microbiota play an important role in pathogenesis, with bacterial species recently shown to accurately differentiate between NAFL and NASH patients; (3) the main drivers of liver cell injury are lipotoxicity caused by free fatty acids (FFAs) and their derivatives combined with mitochondrial dysfunction; (4) decreased endoplasmic reticulum (ER) efficiency with increased demand for protein synthesis/folding/repair results in ER stress, protracted unfolded protein response, and apoptosis; (5) upregulated proteins involved in multiple pathways including JNK, CHOP, PERK, BH3-only proteins, and caspases result in mitochondrial dysfunction and apoptosis; and (6) subtypes of NASH in which these pathophysiological pathways vary may require patient subtype identification to choose effective therapy. SUMMARY: Recent pathogenesis studies may lead to important therapeutic advances, already seen in patients treated with ACC, ASK1 and SCD1 inhibitors and FXR agonists. Further advancing our understanding of mechanisms underlying NASH pathogenesis and the complex interplay between them will be crucial for developing effective therapies.
Authors: Elizabeth Tomlinson; Ling Fu; Linu John; Bruce Hultgren; Xiaojian Huang; Mark Renz; Jean Philippe Stephan; Saio Ping Tsai; Lyn Powell-Braxton; Dorothy French; Timothy A Stewart Journal: Endocrinology Date: 2002-05 Impact factor: 4.736
Authors: Elif Arioglu Oral; Vinaya Simha; Elaine Ruiz; Alexa Andewelt; Ahalya Premkumar; Peter Snell; Anthony J Wagner; Alex M DePaoli; Marc L Reitman; Simeon I Taylor; Phillip Gorden; Abhimanyu Garg Journal: N Engl J Med Date: 2002-02-21 Impact factor: 91.245
Authors: Maurice G Emery; Jeannine M Fisher; Jenny Y Chien; Evan D Kharasch; E Patchen Dellinger; Kris V Kowdley; Kenneth E Thummel Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: Ariel E Feldstein; Ali Canbay; Paul Angulo; Makiko Taniai; Lawrence J Burgart; Keith D Lindor; Gregory J Gores Journal: Gastroenterology Date: 2003-08 Impact factor: 22.682
Authors: Ariel E Feldstein; Nathan W Werneburg; Ali Canbay; Maria Eugenia Guicciardi; Steven F Bronk; Robert Rydzewski; Laurence J Burgart; Gregory J Gores Journal: Hepatology Date: 2004-07 Impact factor: 17.425
Authors: Ling Fu; Linu M John; Sean H Adams; Xing Xian Yu; Elizabeth Tomlinson; Mark Renz; P Mickey Williams; Robert Soriano; Racquel Corpuz; Barbara Moffat; Richard Vandlen; Laura Simmons; Jessica Foster; Jean-Philippe Stephan; Siao Ping Tsai; Timothy A Stewart Journal: Endocrinology Date: 2004-02-19 Impact factor: 4.736